Small molecule · Inhibitor of histone deacetylase (HDAC9) · developed by Biodexa Pharmaceuticals
MTX110 is a gold nanoparticle formulation of panobinostat, a pan-histone deacetylase inhibitor, designed for intra-tumoral injection. It delivers panobinostat directly to brain tumors, bypassing the blood-brain barrier, to inhibit HDAC and induce histone hyperacetylation, leading to chromatin remodeling and tumor cell apoptosis. It is studied in recurrent glioblastoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05324501 | Phase 1 | Recurrent Glioblastoma | Terminated | BDRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Recurrent Glioblastoma
See BDRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BDRX catalysts and pipeline →